- Approval Id
- 78c945ece7f11786
- Drug Name
- TEVETEN TABLET 600 MG
- Product Name
- TEVETEN TABLET 600 MG
- Approval Number
- SIN11807P
- Approval Date
- 2002-02-21
- Registrant
- ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED
- Licence Holder
- ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED
- Drug Type
- Therapeutic
- Forensic Classification
- PRESCRIPTION ONLY MEDICINES
- Dosage Form
- TABLET, FILM COATED
- Dosage
- <p><u><strong>Posology and method of administration</strong></u></p>
<p>The recommended dose is 600 mg once daily, to be taken in the morning.</p>
<p>The dose may be increased to a maximum of 800 mg daily, depending on the blood pressure response, until satisfactory response is achieved. Achievement of maximal blood pressure reduction in most patients may take 2 to 3 weeks of treatment.</p>
<p>Doses up to 1200 mg per day, for 8 weeks, have been shown in clinical trials to be effective with no apparent dose relationship in the incidence of adverse experiences reported.</p>
<p>Teveten™ may be used alone or in combination with other antihypertensives, e.g. thiazide-type diuretics or calcium channel blockers, if a greater blood pressure lowering effect is required.</p>
<p>Teveten™ may be taken with or without food.</p>
<p>Elderly (> 75 years): As clinical experience is limited in patients over 75 years, a starting dose of 300 mg once daily is recommended.</p>
<p>Dosage in hepatically impaired patients: There is limited experience in patients with hepatic impairment (see section Contra-indications and section Pharmacokinetic properties – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>). In patients with mild to moderate hepatic impairment, a starting dose of 300 mg once daily is recommended.</p>
<p>Dosage in renally impaired patients: No dose adjustment is required in patients with creatinine clearance 60–80 ml/min. As clinical experience is limited in patients with creatinine clearance <60ml/min, a starting dose of 300mg once daily is recommended (see Special warnings and precautions for use – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p>
- Route Of Administration
- ORAL
- Indication Info
- <p><u><strong>Indication</strong></u></p>
<p>Treatment of essential hypertension.</p>
- Contraindications
- <p><u><strong>Contra-indications</strong></u></p>
<p>Known hypersensitivity to components of the product. Pregnancy and lactation. Severe hepatic impairment.</p>
<p>The concomitant use of Teveten™ with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73m<sup>2</sup>) (see Interactions – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p>
- Atc Code
- C09CA02
- Atc Item Name
- eprosartan
- Pharma Manufacturer Name
- ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED
- Company Detail Path
- /organization/abbott-laboratories-singapore-private-limited
